» Articles » PMID: 33519761

Evaluation of the Immunochromatographic NG-Test Carba 5, RESIST-5 O.O.K.N.V., and IMP -SeT for Rapid Detection of KPC-, NDM-, IMP-, VIM-type, and OXA-48-like Carbapenemase Among

Overview
Journal Front Microbiol
Specialty Microbiology
Date 2021 Feb 1
PMID 33519761
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Background: are the most common pathogens for nosocomial infections. The emergence and spread of KPC, NDM, and OXA-48-like carbapenemase-producing with their extensively drug-resistant characteristics have posed great threats to public health. This study aimed to evaluate the performance of NG-test Carba 5, RESIST-5 O.O.K.N.V., and IMP -SeT for rapid detection of five carbapenemases (KPC, NDM, VIM, IMP, and OXA-48-like) among .

Methods: A total of 186 carbapenem-resistant clinical isolates and 29 reference strains were used in this study. Carbapenemase genes were confirmed by PCR and DNA sequencing. The sensitivities and specificities of these assays were calculated utilizing the VassarStats software.

Results: For clinical isolates, the NG-test Carba 5 detected KPC, NDM, OXA-48-like, IMP, and VIM in less than 15 min with the sensitivity and specificity of 100% and 100%, respectively. The RESIST-5 O.O.K.N.V. detected KPC, NDM, OXA-48-like, and VIM with the sensitivity and specificity of 99.4 and 100%. The IMP -SeT detected all of the IMP producers (6/6). For reference strains, the sensitivity and specificity of NG-test Carba 5, RESIST-5 O.O.K.N.V., and IMP -SeT were all 100 and 100%, respectively.

Conclusion: As efficient, rapid, and convenient diagnostic methods, NG-test Carba 5, RESIST-5 O.O.K.N.V., and IMP -SeT could help to simplify the complex routine workflow for detecting carbapenemases. Rapid and accurate identification of carbapenemase is of significance for both epidemiological and infection control purposes.

Citing Articles

Detection of antimicrobial resistance via state-of-the-art technologies versus conventional methods.

Elbehiry A, Marzouk E, Abalkhail A, Abdelsalam M, Mostafa M, Alasiri M Front Microbiol. 2025; 16:1549044.

PMID: 40071214 PMC: 11893576. DOI: 10.3389/fmicb.2025.1549044.


Exploring New Delhi Metallo Beta Lactamases in Klebsiella pneumoniae and Escherichia coli: genotypic vs. phenotypic insights.

Ain N, Elton L, Sadouki Z, McHugh T, Riaz S Ann Clin Microbiol Antimicrob. 2025; 24(1):12.

PMID: 39923059 PMC: 11806598. DOI: 10.1186/s12941-025-00775-x.


Comparative analysis of selected methods of carbapenemase determination among clinical Klebsiella pneumoniae.

Pruss A, Skierska A, Kwiatkowski P, Masiuk H, Jursa-Kulesza J, Giedrys-Kalemba S PLoS One. 2025; 20(2):e0318852.

PMID: 39919082 PMC: 11805415. DOI: 10.1371/journal.pone.0318852.


Laboratory detection of carbapenemases among Gram-negative organisms.

Simner P, Pitout J, Dingle T Clin Microbiol Rev. 2024; 37(4):e0005422.

PMID: 39545731 PMC: 11629623. DOI: 10.1128/cmr.00054-22.


In vitro Synergistic and Bactericidal Effects of Aztreonam in Combination with Ceftazidime/ Avibactam, Meropenem/Vaborbactam and Imipenem/Relebactam Against Dual-Carbapenemase-Producing .

Fu Y, Zhu Y, Zhao F, Yao B, Yu Y, Zhang J Infect Drug Resist. 2024; 17:3851-3861.

PMID: 39247757 PMC: 11380864. DOI: 10.2147/IDR.S474150.


References
1.
Zusman O, Altunin S, Koppel F, Dishon Benattar Y, Gedik H, Paul M . Polymyxin monotherapy or in combination against carbapenem-resistant bacteria: systematic review and meta-analysis. J Antimicrob Chemother. 2016; 72(1):29-39. DOI: 10.1093/jac/dkw377. View

2.
Tsai Y, Wang S, Chiu H, Kao C, Wen L . Combination of modified carbapenem inactivation method (mCIM) and EDTA-CIM (eCIM) for phenotypic detection of carbapenemase-producing Enterobacteriaceae. BMC Microbiol. 2020; 20(1):315. PMC: 7568406. DOI: 10.1186/s12866-020-02010-3. View

3.
Shirley M . Ceftazidime-Avibactam: A Review in the Treatment of Serious Gram-Negative Bacterial Infections. Drugs. 2018; 78(6):675-692. DOI: 10.1007/s40265-018-0902-x. View

4.
Bassetti M, Giacobbe D, Giamarellou H, Viscoli C, Daikos G, Dimopoulos G . Management of KPC-producing Klebsiella pneumoniae infections. Clin Microbiol Infect. 2017; 24(2):133-144. DOI: 10.1016/j.cmi.2017.08.030. View

5.
Yin D, Wu S, Yang Y, Shi Q, Dong D, Zhu D . Results from the China Antimicrobial Surveillance Network (CHINET) in 2017 of the Activities of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Clinical Isolates of and . Antimicrob Agents Chemother. 2019; 63(4). PMC: 6437533. DOI: 10.1128/AAC.02431-18. View